Building Resilient Clinical Trial Supply Chains In An Era Of Geopolitical Risk

By Steve Beda, global supply chain & logistics transformation advisor

The global supply chain has become the backbone of modern clinical trials, enabling the movement of investigational drugs, biologics, and critical materials across borders at an unprecedented scale. But this interconnected system also introduces significant exposure to disruption.

From geopolitical instability and regulatory shifts to logistics breakdowns and natural disasters, today’s clinical trial supply chains operate in an environment defined by uncertainty. And when patient outcomes and trial timelines are on the line, resilience is no longer optional. It is essential. In practice, this means ensuring investigational product is consistently available at the site level, where even short disruptions can delay patient dosing or protocol adherence. In many organizations, this responsibility sits with the clinical supply manager, who monitors site inventory thresholds and ensures resupply is triggered before minimum stock levels are reached.

Geopolitical Risk Is Now A Core Supply Chain Variable

In recent years, geopolitical events have moved from background noise to active disruptors of global clinical trial operations.

Trade restrictions, sanctions, regional conflicts, and shifting regulatory frameworks can all interrupt the flow of clinical materials with little warning. Unlike traditional manufacturing supply chains, clinical trials are particularly sensitive to these disruptions due to strict temperature controls, limited product shelf life, and tightly coordinated timelines. For example, a sudden change in import regulations in a clinical trial country can delay customs clearance, forcing clinical supply teams to hold shipments at intermediate hubs or reallocate inventory from regional depots to prevent site stockouts. These decisions are often triggered when projected depot inventory falls below predefined safety stock levels based on enrollment forecasts and dosing schedules.

This is where risk moves from theoretical to operational.

Organizations must now treat geopolitical intelligence as a core input into supply chain design, not a reactive consideration. This often requires incorporating country-level risk into initial depot placement, labeling strategy, and comparator sourcing decisions before a study even begins. For example, supply planners may choose to position inventory in multiple regional depots rather than a single central location to reduce dependency on any one trade route.

The Fragility Of Global Clinical Supply Networks

Clinical trial supply chains are inherently complex. They rely on a highly coordinated network of manufacturers, logistics providers, 3PLs, and research sites distributed across multiple regions. While some products (supplies) can be shipped via more of a commodity service, many have special requirements that only trusted, reliable, and scalable carriers/LSPs can handle. These requirements often include temperature-controlled packaging, validated shipping lanes, and strict chain-of-custody documentation to maintain GMP compliance. In addition, materials often require country-specific labeling or QP release before distribution, adding further dependency on regulatory timelines.

This interconnectedness creates efficiency but also vulnerability.

As we’ve seen across global logistics systems, disruptions rarely occur in isolation. A single geopolitical event can cascade across multiple nodes of the supply chain, simultaneously impacting production, transportation, and site-level execution. For instance, a delay in releasing a manufacturing batch due to regulatory inspection can compress timelines for labeling, distribution to depots, and subsequent site resupply, increasing the risk that IRT-triggered shipments cannot be fulfilled on schedule. When this occurs, supply teams may need to prioritize limited inventory for high-enrolling sites or patients ahead of dosing cycles to avoid personal deviations.

This is why visibility is critical.

Without end-to-end transparency across the network, organizations cannot identify risk exposure early enough to respond effectively. End-to-end visibility in this context includes real-time insight into depot inventory levels, in-transit shipment status, and site-level demand signals driven by patient enrollment and dosing schedules. These data streams are typically reviewed daily by supply planners to assess whether upcoming resupply triggers can be met under current conditions.

From Reactive Response To Proactive Resilience

Historically, supply chain risk management has been reactive, responding after a disruption occurs. But in clinical trials, that model is no longer viable.

Instead, organizations must move toward proactive resilience planning. That means building the infrastructure before you need it, not after. This includes:

• supply chain mapping across all trial materials and regions
• scenario planning for geopolitical and logistical disruptions
• diversification of suppliers and manufacturing locations
• real-time monitoring of shipments and conditions
• contingency planning for regulatory or trade interruptions
• proper monitoring of transportation logistics providers in all regions.

In clinical trial supply, these activities often translate into modeling depot stocking strategies under different enrollment scenarios, prequalifying backup distribution routes, and establishing buffer stock levels to protect against delays in customs clearance or lane disruptions. These models are often recalibrated as enrollment rates change, requiring ongoing adjustments to manufacturing and distribution plans.

This approach allows organizations to anticipate disruption rather than simply absorb it. It also enables faster execution of mitigation strategies such as rebalancing inventory across depots or prioritizing shipments to high-enrolling sites. Such rebalancing decisions are typically made within defined review cycles or triggered by exception alerts in supply planning systems.

The Role Of Data And Real-Time Intelligence

Effective resilience depends on data, specifically the ability to connect financial, operational, and logistics information into a unified view of the supply chain.

I see this as one of the most critical evolutions happening in clinical supply chain management right now. Organizations need real-time visibility into spend, movement, and performance across their global logistics networks to understand where vulnerabilities exist and how to respond quickly. This includes integrating data from IRT systems, depot inventory management platforms, shipment tracking tools, and temperature monitoring devices to create a single operational picture. This integration allows teams to compare planned versus actual inventory positions and quickly identify deviations that could impact site supply.

When geopolitical disruption occurs, speed matters. The ability to see impact in real time enables faster decision-making, rerouting, and mitigation. For example, if shipment tracking data indicates a delay at a border crossing, teams can proactively trigger resupply from an alternate depot before site inventory reaches critical thresholds. These thresholds are often defined as a minimum number of dosing days remaining at the site level.

AI And Predictive Risk Modeling In Clinical Supply Chains

Artificial intelligence is increasingly playing a role in strengthening supply chain resilience.

AI-driven systems can:

• identify emerging geopolitical risks based on global data signals
• predict potential delays in key trade lanes
• optimize routing decisions based on risk exposure
• flag anomalies in shipment movement or timing.

In a clinical trial setting, this can mean identifying that a specific trade lane is at elevated risk and proactively shifting shipments to alternative routes or adjusting depot allocations to maintain continuity of supply. In some cases, this may also trigger earlier-than-planned manufacturing runs if projected supply risk exceeds acceptable thresholds.

This shifts supply chain management from reactive problem-solving to predictive risk mitigation.

For clinical trials, where delays can impact patient recruitment and regulatory timelines, this capability is especially valuable. It also supports more accurate forecasting by incorporating external risk signals alongside enrollment and dosing data.

Build A Resilient Future For Clinical Trials

The future of clinical trial supply chains will be defined by adaptability.

Organizations that succeed will be those that integrate risk intelligence, real-time data, and AI-driven decision-making into every layer of their supply chain operations. This is true operationalization of the data. At a practical level, this means embedding these capabilities into day-to-day workflows such as demand planning, depot replenishment, and shipment execution rather than treating them as separate analytical exercises. This includes embedding alerts and decision support directly into the systems used by clinical supply teams rather than relying on manual analysis.

Geopolitical risk is not going away, but its impact can be managed. I have seen this firsthand, working with organizations navigating some of the most complex global logistics environments in any industry. With the right visibility, systems, and strategy, clinical trial supply chains can move from fragile and reactive to intelligent and resilient.

In global clinical trials, resilience isn’t just operational. It is the difference between a trial that runs on schedule and one that doesn't.

About The Author:

Steve Beda is a global supply chain and logistics expert with more than 20 years of experience leading enterprise transformation and driving operational efficiency for major organizations. He specializes in optimizing data and financial flows across the supply chain, with deep expertise in freight strategy, transportation cost reduction, and retail logistics. Steve has successfully advised Fortune 500 companies on planning and execution strategies that streamline operations, reduce costs, and improve sustainability. A recognized thought leader and frequent podcast guest, he is known for translating complex industry trends and challenges into actionable insights that help businesses innovate and stay competitive.